# A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to Standard of Care Basal Insulin in Patients Already Using Basal Insulin

Study · id `cardio:ct-nct02967211` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02967211](<https://clinicaltrials.gov/study/NCT02967211>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02967211

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 609 participants.

## Technical summary

Registry record NCT02967211. Randomized; no masking; primary purpose treatment. Start 2015-12-21 (registry gives no type); primary completion 2017-10-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 609 participants (enrolled count; ClinicalTrials.gov record NCT02967211, source copy `cardio:ctgov-nct02967211-2022-04-25`, retrieved 2026-10-26)
- Start date: 2015-12-21 (registry gives no type) (ClinicalTrials.gov record NCT02967211, source copy `cardio:ctgov-nct02967211-2022-04-25`, retrieved 2026-10-26)
- Primary completion: 2017-10-20 (actual) (ClinicalTrials.gov record NCT02967211, source copy `cardio:ctgov-nct02967211-2022-04-25`, retrieved 2026-10-26)
- Completion: 2017-10-20 (actual) (ClinicalTrials.gov record NCT02967211, source copy `cardio:ctgov-nct02967211-2022-04-25`, retrieved 2026-10-26)
- Countries: Brazil; Finland; France; Greece; Ireland; Italy; Romania; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT02967211, source copy `cardio:ctgov-nct02967211-2022-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02967211-2022-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin
- Acronym: REGAIN CONTROL
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): insulin glargine (U300)
- Intervention (Drug): insulin glargine (U100)
- Intervention (Drug): NPH insulin
- Intervention (Drug): insulin detemir
- Intervention (Drug): insulin degludec
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 320f912e0ec21585215e2c1ea2cce1b3dd1d9a1b9216a50d962c90186e840ac8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
